Comparative Pharmacology
Head-to-head clinical analysis: KERYDIN versus TOLAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERYDIN versus TOLAK.
KERYDIN vs TOLAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
TOLAK (tazarotene) is a retinoid prodrug that is converted to its active metabolite tazarotenic acid, which binds selectively to retinoic acid receptors (RARs) such as RARβ and RARγ; this modulates gene expression involved in cell proliferation, differentiation, and inflammation.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
Adults: 200 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
The terminal elimination half-life of fluorouracil is approximately 10-20 minutes due to rapid catabolism by dihydropyrimidine dehydrogenase. Clinically, this short half-life necessitates continuous infusion for sustained systemic exposure.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Tolak (fluorouracil) is primarily eliminated via metabolism; less than 10% is excreted unchanged in urine. Fecal excretion accounts for approximately 10-20% of the administered dose.
Category C
Category C
Antifungal
Antifungal